Pfizer (PFE) Raises 2026 Guidance Despite Stock Dip and Pandemic Product Weakness

Key Takeaways

Table of Contents

Third-quarter revenue totaled $16.6 billion as Pfizer’s newly launched medicines contributed significant gains.
The pharmaceutical giant lifted its 2026 annual revenue forecast to a range of $62 billion–$64 billion.
Growth leaders included Eliquis, Padcev, and Lorbrena, strengthening the company’s diversified product lineup.
COVID-19 treatments saw steep declines: Paxlovid fell 63% and Comirnaty dropped 29% year-over-year.
Adjusted earnings per share held steady at $0.87, with management upgrading annual EPS projections.

Shares of Pfizer Inc. (NYSE: PFE) fell 1.84% to close at $30.10, losing $0.57 in Tuesday’s trading session. The drop occurred despite the drugmaker posting third-quarter 2026 sales of $16.6 billion and demonstrating robust momentum in its recently introduced therapeutic portfolio. Management responded to the performance by elevating both revenue and earnings projections for the full fiscal year.

Pfizer Inc., PFE

Third-Quarter Sales Reach $16.6 Billion

Pfizer recorded third-quarter revenue of $16.583 billion, slightly below the $16.654 billion achieved in the corresponding 2025 period. While headline revenue appeared essentially unchanged, the picture improved when adjusting for pandemic-related offerings, with operational revenue climbing 7% after removing Comirnaty and Paxlovid from calculations.

The company’s recently introduced and acquired medicines posted impressive operational revenue expansion of 32% during the three-month period. This strength in newer assets helped counterbalance softness in legacy treatments and demonstrated progress in portfolio transformation. Through the first three quarters of 2026, Pfizer accumulated $46.067 billion in total revenue, marking a 2% year-over-year advance.

Reported diluted earnings per share came in at $0.56, representing a 9% decline from the prior-year figure of $0.62. Conversely, adjusted diluted EPS maintained stability at $0.87 compared to the same quarter last year. On an adjusted basis, income rose 1% to $4.985 billion, while reported net income decreased 8% to $3.242 billion.

Newer Medicines Compensate for Pandemic Product Erosion

Multiple key medicines within Pfizer’s portfolio delivered meaningful sales increases that bolstered the quarter’s commercial results. Eliquis brought in an additional $513 million compared to the prior year, achieving 25% operational growth. This expansion stemmed from favorable US pricing adjustments and increased worldwide utilization, though generic alternatives impacted certain overseas territories.

Padcev sales climbed 55% operationally to $255 million above last year’s benchmark. The oncology treatment benefited from enhanced penetration in first-line bladder cancer applications and continued adoption across supplementary approved uses. Additionally, the Vyndaqel franchise advanced 12% operationally, propelled by broader insurance coverage and rising patient numbers.

Revenue from Nurtec ODT and Vydura jumped 33% operationally, while Lorbrena surged 43%. However, the company’s COVID-19 franchise continued its substantial contraction. Paxlovid sales plummeted 63%, translating to a $771 million operational decrease, and Comirnaty revenue declined 29%, equating to $339 million in lost sales.

The Prevnar vaccine series also experienced a 10% operational revenue reduction, attributed to diminished vaccination frequency and competitive pressures. These setbacks partially negated gains from emerging products. Still, Pfizer managed to preserve relatively consistent quarterly sales through diversification across multiple therapeutic areas outside the pandemic category.

Annual Financial Outlook Receives Upward Revision

Capitalizing on its third-quarter momentum, Pfizer elevated its full-year 2026 revenue expectations. The updated range now stands at $62 billion to $64 billion, up from the earlier $60.5 billion to $62.5 billion projection. This modification reflects a $1.5 billion improvement at the midpoint of the guidance range.

Pfizer simultaneously refined its adjusted diluted EPS guidance upward to a band of $2.95–$3.05. The previous estimate ranged from $2.80 to $3.00. Management noted that the revised forecast incorporates a one-time $650 million research and development expense connected to its partnership with Innovent Biologics.

The pharmaceutical company anticipates adjusted research and development expenditures will fall between $10.8 billion and $11.8 billion for the year. Concurrently, adjusted selling, informational, and administrative costs are projected to land within a $12.5 billion to $13.5 billion range. Management also reaffirmed its expectation for an adjusted effective tax rate of roughly 15%.

Strategic Investment and Shareholder Returns Continue

Pfizer sustained significant capital deployment toward innovation, expansion, and shareholder distributions throughout 2026. Internal research and development initiatives absorbed $8.3 billion during the initial nine months of the year. An additional $850 million approximately supported business development activities, predominantly channeled through the Innovent Biologics strategic arrangement.

Pfizer distributed $7.3 billion to equity holders via cash dividends over the same timeframe. This equated to $1.29 per common share, underscoring management’s commitment to consistent dividend payments. The company refrained from executing any share buybacks during 2026, leaving $3.3 billion in remaining repurchase authorization.

Concurrently, Pfizer progressed its late-stage clinical pipeline by initiating eight pivotal trials, completing one pivotal study readout, and securing two regulatory decisions. Its investigational programs span oncology, immunology, vaccines, and metabolic conditions including obesity. These initiatives position the company to broaden its commercial offering and generate additional revenue streams in coming years.